Kheoba Corp. (KHOB)

CTI BioPharma Balance Sheet

Financials in millions USD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021
Cash & Equivalents	0.04	0	0.02	0	0.01
Cash & Short-Term Investments	0.04	0	0.02	0	0.01
Cash Growth	2805.41%	-93.46%	736.81%	-66.58%	-
Prepaid Expenses	0.01	0.02	0.01	-	-
Total Current Assets	0.32	0.02	0.03	0	0.01
Other Intangible Assets	0.01	0.02	0	0	-
Total Assets	0.39	0.04	0.03	0.01	0.01
Accounts Payable	0.08	0.02	0	0	-
Short-Term Debt	-	0.02	0	0	0
Current Unearned Revenue	-	-	0	-	-
Total Current Liabilities	0.14	0.03	0.01	0.01	0
Total Liabilities	0.17	0.03	0.01	0.01	0
Common Stock	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	0.08	0.04	0.02	-	-
Retained Earnings	0.13	-0.04	-0.01	-0.01	-0
Shareholders' Equity	0.22	0	0.02	-0	0.01
Total Liabilities & Equity	0.39	0.04	0.03	0.01	0.01
Total Debt	0.05	0.02	0	0	0
Net Cash (Debt)	-0.01	-0.02	0.01	-0	0.01
Net Cash Per Share	-0.00	-0.00	0.00	-0.00	0.00
Filing Date Shares Outstanding	8.09	8.09	8.09	6	6
Total Common Shares Outstanding	8.09	8.09	7.3	6	6
Working Capital	0.18	-0.01	0.02	-0.01	0.01
Book Value Per Share	0.03	0.00	0.00	-0.00	0.00
Tangible Book Value	0.2	-0.01	0.02	-0.01	0.01
Tangible Book Value Per Share	0.03	-0.00	0.00	-0.00	0.00

Source: S&P Global Market Intelligence. Standard template. Financial Sources.